Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 15
2004 42
2005 70
2006 71
2007 94
2008 122
2009 103
2010 88
2011 74
2012 148
2013 218
2014 203
2015 202
2016 193
2017 191
2018 166
2019 69
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,731 results
Results by year
Filters applied: . Clear all
Page 1
Endocannabinoid System: A Multi-Facet Therapeutic Target
Kaur R, et al. Curr Clin Pharmacol 2016 - Review. PMID 27086601
Presently, cannabinoid receptor agonists like nabilone and dronabinol are used for reducing the chemotherapy induced vomiting. ...Another angle to be introspected for therapeutic abilities of this group of drugs is non-CB1 and non-CB2 receptor targets for cannabinoids. ...
Presently, cannabinoid receptor agonists like nabilone and dronabinol are used for reducing the chemotherapy induced vomiting. …
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
Khurana L, et al. Neuropharmacology 2017 - Review. PMID 28527758 Free PMC article.
The identification of allosteric modulators of the cannabinoid receptor 1 (CB(1)) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s). Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics. Here we briefly discuss the first-generation of allosteric modulators of CB(1) receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB(1) receptor. ...
The identification of allosteric modulators of the cannabinoid receptor 1 (CB(1)) has given a new direction to the deve …
An Introduction to the Endogenous Cannabinoid System.
Lu HC and Mackie K. Biol Psychiatry 2016 - Review. PMID 26698193 Free PMC article.
The most abundant cannabinoid receptors are the CB1 cannabinoid receptors; however, CB2 cannabinoid receptors, transient receptor potential channels, and peroxisome proliferator activated receptors are also engaged by some cannabinoids. Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects through their interactions with cannabinoid receptors. ...
The most abundant cannabinoid receptors are the CB1 cannabinoid receptors; however, CB2 cannabinoid receptors, transien …
Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System.
Zou S and Kumar U. Int J Mol Sci 2018 - Review. PMID 29533978 Free PMC article.
The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. ...We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids....
The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediate …
The Endocannabinoid System and its Modulation by Phytocannabinoids
Di Marzo V and Piscitelli F. Neurotherapeutics 2015 - Review. PMID 26271952 Free PMC article.
The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ(9)-tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)-cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R); their two most studied endogenous ligands, the "endocannabinoids" N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. ...Finally, some of the metabolic enzymes may also participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets. ...
The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ(9)-t …
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
Boggs DL, et al. Neuropsychopharmacology 2018 - Review. PMID 28875990 Free PMC article.
In this article, we review the available evidence on the pharmacology and behavioral interactions of THC and CBD from preclinical and human studies, particularly with reference to anxiety and psychosis-like symptoms. Both THC and CBD, as well as other cannabinoid molecules, are currently being evaluated for medicinal purposes, separately and in combination. ...
In this article, we review the available evidence on the pharmacology and behavioral interactions of THC and CBD from preclinical and …
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD and Connor M. Handb Exp Pharmacol 2018. PMID 30105473
Synthetic cannabinoid receptor agonists (SCRAs) are the largest and most structurally diverse class of new psychoactive substances (NPS). ...Most SCRAs potently activate cannabinoid type 1 and type 2 receptors (CB(1) and CB(2), respectively), with the former contributing to the psychoactivity of these substances. ...
Synthetic cannabinoid receptor agonists (SCRAs) are the largest and most structurally diverse class of new psychoactive substa …
Translational potential of allosteric modulators targeting the cannabinoid CB(1) receptor.
Lu D, et al. Acta Pharmacol Sin 2019 - Review. PMID 30333554 Free PMC article.
The cannabinoid type-1 (CB(1)) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiological processes. ...In this paper, we review and summarize the complex pharmacological profiles of each class of CB(1) allosteric modulators, the development of new classes of CB(1) allosteric modulators and the results from in vivo assessments of their therapeutic value....
The cannabinoid type-1 (CB(1)) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due t …
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Banister SD and Connor M. Handb Exp Pharmacol 2018 - Review. PMID 29980914
Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. ...Characterization of the pharmacology and toxicology of these substances is hindered by the dynamic nature of the SCRA marketplace. ...
Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. . …
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
Morales P, et al. Expert Opin Ther Pat 2016 - Review. PMID 27215781
INTRODUCTION: Modulation of the CB2 receptor is an interesting approach for pain and inflammation, arthritis, addictions, neuroprotection, and cancer, among other possible therapeutic applications, and is devoid of central side effects. AREAS COVERED: This review highlights the novel scaffolds for CB2 ligands and the diverse therapeutic applications for CB2 modulators disclosed in patents published since 2012. ...
INTRODUCTION: Modulation of the CB2 receptor is an interesting approach for pain and inflammation, arthritis, addictions, neuroprotec …
1,731 results
Jump to page
Feedback